Wenyan Lü

The paper identifies W2A-28, a dual modulator of class I HDACs and Wnt/β-catenin signaling, as a potential therapeutic for Alzheimer's disease.

This paper describes the discovery and validation of C273, a mitochondrial complex I modulator that reduces Alzheimer's disease pathology by enhancing cellular resilience through AMPK-mediated pathways.

The paper assesses a novel mitochondrial complex I inhibitor, C458, in vitro and in vivo, showing it protects against Aβ toxicity, improves brain energetics, and reduces inflammation in Alzheimer's disease models.